IQVIA Laboratories is a company that provides integrated lab services covering from the early stages of drug discovery to the clinical phase. For non-clinical studies, in addition to conducting tests in-house, they have a system in place to support the entire development process by handling everything from custom model development to analysis. This section introduces the features of IQVIA Laboratories' non-clinical studies.
One of the significant strengths of IQVIA Laboratories' preclinical testing services is its flexible study design capabilities, centered around the development of custom in vivo models. Rather than relying on existing standard models,Design and construct appropriate disease models according to the target disease, mechanism of action, and endpoints to be evaluated.We have established a system to support research. We cover a wide range of fields, including infectious diseases, tumors, and immune disorders, and can modify models and optimize conditions according to research objectives. Furthermore, specialists in immunology and molecular biology are involved from the study design stage to construct an integrated evaluation system that combines in vivo studies with various bioassays. We achieve the generation of highly reproducible and practical data, with a view to bridging from early drug discovery to clinical application.
By combining high-throughput ADME (Absorption, Distribution, Metabolism, Excretion) testing with advanced bioanalysis, we improve development efficiency in the preclinical stage. Leveraging automated testing platforms,Rapid and parallel evaluation of numerous compoundsThis allows for the early screening of promising candidates. By comprehensively analyzing metabolite identification, drug-drug interactions, and biomarker measurements, drug properties can be understood from multiple angles. A system is in place to reduce risks after clinical transition and expedite decision-making, thereby supporting the overall efficiency of the drug discovery process.
We have established lab operations that comply with GLP (Good Laboratory Practice) and a testing system that meets international standards.We can provide high-quality data with regulatory submission in mind.All types of studies, including bioanalysis, are conducted under standardized procedures to ensure data reliability and reproducibility. Furthermore, our animal testing facilities are operated in consideration of international guidelines, meeting the standards required for global development. By leveraging our global network of facilities, we can design studies and build data packages that comply with regional regulatory requirements. We support efficient project advancement for international joint development and country-specific applications.
LCMV models areRepresentative in vivo models for evaluating immune responses to viral infectionsIQVIA Laboratories utilizes it as a challenge study in a BSL-2 environment, serving to evaluate the efficacy of vaccines and immunotherapies. A key feature is its ability to analyze both cellular immunity (T-cell response) and humoral immunity. It is positioned as a foundational model for preclinical evaluation in the infectious disease field.
Oncogenic proliferation modelsAn in vivo model for evaluating the efficacy of anticancer drugs and immune checkpoint inhibitorsAt IQVIA Laboratories, treatment efficacy is verified using indicators such as tumor growth inhibition and changes in immune response. This is particularly utilized in the field of immuno-oncology for analyzing drug mechanisms of action and exploring combination therapies. It plays a crucial role in evaluating efficacy during the preclinical stage.
Information on non-clinical study examples was not available on the official website.
| Address | IQVIA Laboratories Japan K.K.: 2-5-10 Aomi, Koto-ku, Tokyo, Telecom Center Building |
|---|---|
| Tel | 03-6859-9620 |
| Website | https://www.iqvia.com/ja-jp/locations/japan |
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.